ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Islam Saqib (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15239	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock option (right to buy)	$1.27	2030-05-22	Common Stock (25441)		Direct
Stock option (right to buy)	$1.27	2030-05-22	Common Stock (12856)		Direct
Stock option (right to buy)	$1.27	2030-05-22	Common Stock (12398)		Direct

Footnotes

F1: The shares shall vest in 36 equal monthly installments beginning on April 4, 2020.

F2: The shares shall vest in 36 equal monthly installments beginning on October 18, 2020.

F3: The shares shall vest in 36 equal monthly installments beginning on August 1, 2020.